2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

2013 Symposium Photos

2012 Featured Talks

2012 Symposium Photos

2011 Featured Talks

2011 Symposium Photos

Past Symposia in the Press

2012 Featured Talks » Targeting for Glioblastoma Patients with Cilengitide: Promises and Challenges



Targeting for Glioblastoma Patients with Cilengitide: Promises and Challenges


David Reardon, MD, Center for Neuro-Oncology, Dana-Farber Cancer Institute

» Download Audio








David Reardon is clinical director at Dana-Farber Cancer Institute's Center for Neuro-Oncology. His research interests are brain and spinal tumors, clinical trials in neuro-oncology, targeted therapies, anti-angiogenic treatments, immunotherapy, convection-enhanced delivery. His board certifications include Neuro-Oncology, Pediatric Hematology/Oncology, and he completed his fellowship at University of Michigan Hospital, MOTT Children's Hospital, Pediatric Hematology/Oncology in 1992. He completed his residency at John Hopkins Hospital, Pediatrics, in 1989 and received his MD from Tufts Medical School in 1986.